[go: up one dir, main page]

DK109688D0 - 1-hydroxy-3-(n-methyl-n-propylamino)propan-1,1-diphosphonsyre, fremgangsmaade til fremstilling deraf samt laegemidler, der indeholder denne forbindelse - Google Patents

1-hydroxy-3-(n-methyl-n-propylamino)propan-1,1-diphosphonsyre, fremgangsmaade til fremstilling deraf samt laegemidler, der indeholder denne forbindelse

Info

Publication number
DK109688D0
DK109688D0 DK109688A DK109688A DK109688D0 DK 109688 D0 DK109688 D0 DK 109688D0 DK 109688 A DK109688 A DK 109688A DK 109688 A DK109688 A DK 109688A DK 109688 D0 DK109688 D0 DK 109688D0
Authority
DK
Denmark
Prior art keywords
carbon atoms
straight
chain
branched
optionally substituted
Prior art date
Application number
DK109688A
Other languages
English (en)
Other versions
DK109688A (da
DK164281B (da
DK164281C (da
Inventor
Rudi Gall
Elmar Bosies
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6304949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK109688(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of DK109688D0 publication Critical patent/DK109688D0/da
Publication of DK109688A publication Critical patent/DK109688A/da
Publication of DK164281B publication Critical patent/DK164281B/da
Application granted granted Critical
Publication of DK164281C publication Critical patent/DK164281C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK109688A 1986-07-11 1988-03-01 1-hydroxy-3-(n,n-dialkylamino)propan-1,1-diphosphonsyre og derivater heraf, fremgangsmaade til fremstilling deraf, laegemidler, der indeholder disse forbindelser, samt anvendelse af forbindelserne til fremstilling af laegemidler DK164281C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19863623397 DE3623397A1 (de) 1986-07-11 1986-07-11 Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397 1986-07-11
EP8700368 1987-07-09
PCT/EP1987/000368 WO1988000590A1 (fr) 1986-07-11 1987-07-09 Derives d'acide diphosphonique et medicaments les contenant

Publications (4)

Publication Number Publication Date
DK109688D0 true DK109688D0 (da) 1988-03-01
DK109688A DK109688A (da) 1988-03-01
DK164281B DK164281B (da) 1992-06-01
DK164281C DK164281C (da) 1992-11-16

Family

ID=6304949

Family Applications (2)

Application Number Title Priority Date Filing Date
DK350987A DK168629B1 (da) 1986-07-11 1987-07-07 1-hydroxy-omega-aminoalkan-1,1-diphosphonsyrederivater og fremgangsmåde til fremstilling deraf samt lægemidler indeholdende disse forbindelser
DK109688A DK164281C (da) 1986-07-11 1988-03-01 1-hydroxy-3-(n,n-dialkylamino)propan-1,1-diphosphonsyre og derivater heraf, fremgangsmaade til fremstilling deraf, laegemidler, der indeholder disse forbindelser, samt anvendelse af forbindelserne til fremstilling af laegemidler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK350987A DK168629B1 (da) 1986-07-11 1987-07-07 1-hydroxy-omega-aminoalkan-1,1-diphosphonsyrederivater og fremgangsmåde til fremstilling deraf samt lægemidler indeholdende disse forbindelser

Country Status (27)

Country Link
US (2) US4942157A (da)
EP (2) EP0252504B1 (da)
JP (2) JP2563954B2 (da)
KR (2) KR950008997B1 (da)
AT (2) ATE54000T1 (da)
AU (2) AU598279B2 (da)
BG (1) BG60839B2 (da)
CA (2) CA1305166C (da)
CS (1) CS265242B2 (da)
DD (1) DD263992A5 (da)
DE (4) DE3623397A1 (da)
DK (2) DK168629B1 (da)
ES (2) ES2036190T3 (da)
FI (2) FI87221C (da)
GE (1) GEP20084347B (da)
GR (2) GR3000616T3 (da)
HK (1) HK87093A (da)
HU (2) HU201950B (da)
IE (2) IE60219B1 (da)
IL (2) IL83148A (da)
LU (1) LU88844I2 (da)
MX (1) MX9203375A (da)
NL (1) NL960032I2 (da)
NZ (2) NZ221028A (da)
PT (1) PT85301B (da)
WO (1) WO1988000590A1 (da)
ZA (1) ZA874877B (da)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0317505A1 (de) * 1987-11-13 1989-05-24 Ciba-Geigy Ag Neue Azacycloalkylalkandiphosphonsäuren
US5110807A (en) * 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
US5190930A (en) * 1987-12-11 1993-03-02 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
ES2054868T3 (es) * 1987-12-11 1994-08-16 Ciba Geigy Ag Acidos aralifatilaminoalcanodifosfonicos.
JPH07629B2 (ja) * 1988-01-20 1995-01-11 山之内製薬株式会社 （シクロアルキルアミノ）メチレンビス（フォスフォン酸）および該化合物を有効成分とする医薬
US4933472A (en) * 1988-04-08 1990-06-12 Yamanouchi Pharmaceutical Co., Ltd. Substituted aminomethylenebis(phosphonic acid) derivatives
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
WO1990005115A1 (en) * 1988-11-01 1990-05-17 Earl Philip Horwitz Phosphonic acids and their uses in separation
GB8825589D0 (en) * 1988-11-02 1988-12-07 Albright & Wilson Purification
TW198039B (da) * 1988-11-28 1993-01-11 Ciba Geigy Ag
US5154843A (en) * 1989-02-08 1992-10-13 The Lubrizol Corporation Hydroxyalkane phosphonic acids and derivatives thereof and lubricants containing the same
PH26923A (en) * 1989-03-08 1992-12-03 Ciba Geigy N-substituted amino alkanediphosphonic acids
US4987767A (en) * 1989-06-09 1991-01-29 Research Corporation Technologies, Inc. Exposive detection screening system
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21453A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DE69023844T2 (de) * 1989-09-06 1996-06-20 Merck & Co Inc Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
FI89364C (fi) * 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat
IT1244698B (it) * 1991-02-01 1994-08-08 Gentili Ist Spa Acidi aril-o arilalchil-acil ammino-alchil-idrossidifosfonici, procedimento per la loro preparazione e loro uso in terapia osteo-articolare e dei tessuti connettori in generale
ATE164163T1 (de) * 1991-06-19 1998-04-15 Upjohn Co Dialkyl (dialkoxyphosphinyl)methyl phosphate als antientzündungsmittel
IT1247034B (it) * 1991-06-26 1994-12-12 Gentili Ist Spa Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
TW207543B (da) * 1991-08-27 1993-06-11 Ciba Geigy Ag
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
DE4228552A1 (de) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5728650A (en) * 1993-10-07 1998-03-17 Zeneca Limited Herbicidal aza bisphosphonic acids and compositions containing the same
TW401276B (en) * 1993-10-07 2000-08-11 Zeneca Ltd Novel compounds and a method of controlling growth of plants
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5681873A (en) * 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
EP0831756A1 (en) 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
EP0753523A1 (en) 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
PT854724E (pt) * 1995-09-29 2005-08-31 Novartis Ag Metodo de tratar a doenca navicular em cavalos
GB9607945D0 (en) * 1996-04-17 1996-06-19 Univ Nottingham Bisphosponates as Anti-inflammatory agents
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
KR100192215B1 (ko) * 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6255359B1 (en) 1997-12-23 2001-07-03 Board Of Regents Of The University Of Texas System Permeable compositions and methods for their preparation
US6187329B1 (en) 1997-12-23 2001-02-13 Board Of Regents Of The University Of Texas System Variable permeability bone implants, methods for their preparation and use
CN1061661C (zh) * 1997-12-24 2001-02-07 国家医药管理局上海医药工业研究院 (环庚基胺基)亚甲基二膦酸二钠一水合物制备方法
US20020128301A1 (en) * 1998-02-13 2002-09-12 Medivir AB Non-nucleoside reverse transcriptase inhibitors
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
JP3793023B2 (ja) 1998-12-04 2006-07-05 ロシュ ダイアグノスティックス ゲーエムベーハー 体内プロテーゼの骨統合を促進するためのイバンドロネートの使用
ATE293450T1 (de) * 1999-05-21 2005-05-15 Novartis Pharma Gmbh Verwendung von biphosphonsäuren zur behandlung von angiogenese
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
SE0000382D0 (sv) 2000-02-07 2000-02-07 Astrazeneca Ab New process
EP1284754B1 (en) 2000-05-05 2006-01-04 F. Hoffmann-La Roche Ag Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
NZ532994A (en) * 2001-12-21 2008-05-30 Procter & Gamble Method for the treatment of bone disorders using a bisphosphonate regimen, risedronate in particular
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
KR20140021045A (ko) 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
CN1665825A (zh) * 2002-05-17 2005-09-07 特瓦制药工业有限公司 用一定的稀释剂制备双膦酸
AU2003233731A1 (en) * 2002-06-06 2003-12-22 Xavier Billot 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2004019938A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
ES2530791T3 (es) * 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
ES2311142T3 (es) * 2003-01-17 2009-02-01 Teva Pharmaceutical Industries Limited Procedimiento para reducir el contenido de hierro del risedronato sodico.
PL1656386T3 (pl) * 2003-08-21 2010-05-31 Sun Pharmaceuticals Ind Ltd Proces wytwarzania związków kwasu difosfonowego
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
EP1716161B1 (en) * 2003-12-23 2011-05-04 Alchymars S.p.A. Ibandronic acid monosodium salt in the amorphous form
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK1753395T3 (da) 2004-05-24 2010-11-08 Warner Chilcott Co Llc Enterisk, fast, oral doseringsform af et bisphosphonat, der indeholder et chelateringsmiddel
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
US7214818B2 (en) * 2004-10-29 2007-05-08 Hoffmann-La Roche Inc. Method for synthesizing bisphosphonate
JPWO2006062072A1 (ja) * 2004-12-10 2008-08-07 テムリック株式会社 転移癌治療剤および癌転移抑制剤
EP1848727B1 (en) * 2005-02-01 2015-06-17 F.Hoffmann-La Roche Ag Ibandronate polymorph b
CN101111504B (zh) 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a
PT1855674E (pt) 2005-03-02 2014-10-08 Merck Canada Inc Composição para a inibição de catepsina k
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2007013097A1 (en) * 2005-07-25 2007-02-01 Natco Pharma Limited Improved process for the preparation of ibandronate sodium
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
JP5571378B2 (ja) * 2006-06-23 2014-08-13 シプラ・リミテッド イバンドロン酸ナトリウムの合成方法
ES2498519T3 (es) 2006-09-07 2014-09-24 F. Hoffmann-La Roche Ag Un procedimiento para la fabricación de SNAC (SALCAPROZATO SÓDICO)
WO2008060609A1 (en) * 2006-11-16 2008-05-22 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2008074144A1 (en) 2006-12-20 2008-06-26 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
CA2671728C (en) * 2006-12-20 2015-05-26 Genpharm Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
CN101679465B (zh) * 2007-04-11 2013-08-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐的制备方法
CN101679466A (zh) * 2007-04-12 2010-03-24 伊利诺伊大学评议会 对包括fpps、ggpps和dpps在内的多靶点效力提高的二膦酸盐化合物及方法
BRPI0810408A2 (pt) 2007-04-19 2014-11-04 Reddys Lab Ltd Dr Polimorfos de ibandronaro de sódio
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
EP2182875A4 (en) 2007-08-15 2011-08-24 Cardiodex Ltd SYSTEMS AND METHODS FOR PERFORATION CLOSURE
US20090075944A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ibandronate
WO2009042179A1 (en) * 2007-09-24 2009-04-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronic acid and processeses for the preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
WO2009093258A2 (en) * 2008-01-24 2009-07-30 Fleming Laboratories Limited A new and improved process for the preparation of ibandronate sodium monohydrate
CN105055432A (zh) * 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
WO2010035664A1 (ja) * 2008-09-24 2010-04-01 田辺三菱製薬株式会社 ビスホスホン酸誘導体の製法
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
GB0906068D0 (en) 2009-04-07 2009-05-20 King S College London Bisphosphonate Compounds for chelating radionuclides
EP2440250A1 (en) 2009-06-11 2012-04-18 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
BR112012002551A2 (pt) 2009-08-03 2017-06-13 Chimerix Inc composição e métodos de tratamento de infecções virais e tumores induzidos por vírus
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
ES2629165T3 (es) 2010-02-12 2017-08-07 Chimerix, Inc. Métodos de tratamiento de una infección vírica
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201100151A2 (tr) 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut İbandronate formülasyonu.
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
HUE051570T2 (hu) 2011-07-13 2021-03-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Liposzómák biszfoszfonát és amfipatikus szer együtt kapszulázásához
CA2856030A1 (en) 2011-11-16 2013-05-23 Duke University Bisphosphonate compositions and methods for treating and/or reducing cardiac dysfunction
US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
TR201200588A2 (tr) 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
CN103396332A (zh) * 2013-08-19 2013-11-20 四川协力制药有限公司 3—[（n—甲基—n—戊基）氨基]丙酸盐酸盐的制备方法
JP6454335B2 (ja) 2013-10-08 2019-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． カテプシンシステインプロテアーゼ阻害剤
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법
CA3133929A1 (en) 2019-04-19 2020-10-22 Lin Zhi Crystalline forms and methods of producing crystalline forms of a compound
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH9776A (en) * 1967-12-11 1976-03-17 M Francis Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3733270A (en) * 1971-03-08 1973-05-15 Monsanto Co Methods of scale inhibition
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
SU739076A1 (ru) * 1976-05-19 1980-06-05 Институт Химической Кинетики И Горения Со Ан Ссср Способ получени -аминоэтилидендифосфоновых кислот
DE2702631A1 (de) * 1977-01-22 1978-07-27 Henkel Kgaa Verfahren zur herstellung von 1-hydroxy-3-amino-propan-1,1-diphosphonsaeuren
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
SU1002300A1 (ru) * 1981-10-29 1983-03-07 Ордена Ленина институт элементоорганических соединений им.А.Н.Несмеянова Способ получени @ -аминозамещенных- @ -оксипропилидендифосфоновых кислот
DE3365492D1 (en) * 1982-01-27 1986-10-02 Schering Ag Diphosphonic acid derivatives and pharmaceutical preparations containing them
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
EP0096931B1 (en) * 1982-06-10 1987-03-25 Mallinckrodt, Inc. (a Delaware corporation) Radiographic imaging agents
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
NZ221027A (en) 1990-11-27
AU7529187A (en) 1988-01-14
DE3781730D1 (de) 1992-10-22
HK87093A (en) 1993-09-03
EP0252505A1 (de) 1988-01-13
IL83149A0 (en) 1987-12-31
KR960010418B1 (ko) 1996-07-31
DD263992A5 (de) 1989-01-18
CS515787A2 (en) 1989-01-12
DE19675038I2 (de) 2001-08-09
ES2036190T3 (es) 1993-05-16
AU7648787A (en) 1988-02-10
DK109688A (da) 1988-03-01
HU199856B (en) 1990-03-28
ES2043622T3 (es) 1994-01-01
EP0252504B1 (de) 1990-06-20
CS265242B2 (en) 1989-10-13
JPS6323889A (ja) 1988-02-01
EP0252504A1 (de) 1988-01-13
IL83148A (en) 1993-02-21
US4942157A (en) 1990-07-17
IL83148A0 (en) 1987-12-31
GR3000616T3 (en) 1991-09-27
FI87221B (fi) 1992-08-31
FI881134L (fi) 1988-03-10
DK350987A (da) 1988-01-12
DK350987D0 (da) 1987-07-07
JPH082913B2 (ja) 1996-01-17
IL83149A (en) 1992-07-15
KR950008997B1 (ko) 1995-08-10
CA1305166C (en) 1992-07-14
FI85026B (fi) 1991-11-15
GEP20084347B (en) 2008-04-10
IE60345B1 (en) 1994-06-29
HUT47300A (en) 1989-02-28
JP2563954B2 (ja) 1996-12-18
NL960032I1 (nl) 1997-03-03
LU88844I2 (fr) 1997-01-06
DK164281B (da) 1992-06-01
GR3005709T3 (da) 1993-06-07
WO1988000590A1 (fr) 1988-01-28
HU201950B (en) 1991-01-28
PT85301B (pt) 1990-03-30
KR880001687A (ko) 1988-04-26
FI881134A0 (fi) 1988-03-10
CA1296739C (en) 1992-03-03
DE3763314D1 (de) 1990-07-26
ZA874877B (da) 1988-01-13
FI873058A0 (fi) 1987-07-10
DE3623397A1 (de) 1988-01-14
MX9203375A (es) 1992-09-01
IE871862L (en) 1988-01-11
FI873058A7 (fi) 1988-01-12
IE60219B1 (en) 1994-06-15
PT85301A (de) 1987-08-01
HUT44569A (en) 1988-03-28
ATE80633T1 (de) 1992-10-15
FI85026C (fi) 1992-02-25
JPH01500266A (ja) 1989-02-02
IE871861L (en) 1988-01-11
DK164281C (da) 1992-11-16
ATE54000T1 (de) 1990-07-15
AU598569B2 (en) 1990-06-28
NZ221028A (en) 1990-09-26
BG60839B2 (bg) 1996-04-30
NL960032I2 (nl) 1997-08-01
FI87221C (fi) 1992-12-10
AU598279B2 (en) 1990-06-21
DK168629B1 (da) 1994-05-09
EP0252505B1 (de) 1992-09-16
KR880701726A (ko) 1988-11-04
US4927814A (en) 1990-05-22

Similar Documents

Publication Publication Date Title
DK109688D0 (da) 1-hydroxy-3-(n-methyl-n-propylamino)propan-1,1-diphosphonsyre, fremgangsmaade til fremstilling deraf samt laegemidler, der indeholder denne forbindelse
NL300059I1 (nl) Nieuwe difosfonzuurderivaten, werkwijzen voor de bereiding daarvan en deze verbindingen bevattende geneesmiddelen.
IL80570A0 (en) Diphosphonic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing them